Clamart, France — June 8, 2026 — MicroPort CardioFlow Medtech Corporation (02160.HK, “MicroPort CardioFlow”) announced the appointment of Hugues Gervais as Chief Commercial Officer, effective May 18, 2026. He will lead MicroPort CardioFlow’s global commercial strategy and execution as the company continues to expand its international presence and strengthen its position in the cardiovascular medical device market.

Mr. Gervais is a seasoned international executive with more than 25 years in the cardiovascular medical device industry. He brings extensive expertise in strategy, marketing, business development, and commercial leadership, having held senior roles at leading global healthcare organizations. He has deep knowledge across both Structural Heart and Cardiac Rhythm Management.

Over his career, Mr. Gervais has driven the international expansion of cardiovascular businesses, led major product launches, supported periods of accelerated growth, and built high-performing commercial teams in complex, highly regulated environments.

Commenting on his appointment, Hugues Gervais said, "I am excited to join MicroPort CardioFlow at such an important stage in its evolution. The company has built a strong foundation of innovation across Structural Heart and Cardiac Rhythm Management, with significant opportunities for future growth. I look forward to working closely with teams around the world to strengthen our commercial capabilities, expand our global footprint, and bring life-changing technologies to more patients and physicians."

As MicroPort CardioFlow brings together its Cardiac Rhythm Management and Structural Heart businesses, Mr. Gervais’ global experience, strategic vision, and commercial leadership will be valuable assets in accelerating the company’s international development and long-term growth.

About MicroPort CardioFlow:

MicroPort CardioFlow Medtech Corporation (02160.HK) develops innovative technologies for structural heart disease and cardiac rhythm management. With roots in the development of therapies for structural heart disease, the company holds a leading position in China's TAVI market and has built one of the broadest portfolios in the segment.

CardioFlow now combines its structural heart business with MicroPort CRM’s more than 60 years of rhythm management expertise, including 12 core development programs and a global portfolio of over 40 marketed products across pacemakers and ICDs. Together these form an integrated platform spanning structural heart intervention and cardiac rhythm management with a unique synergy to address heart failure.

By providing physicians and patients with innovative, full-cycle cardiac health management, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

More information is available at: https://cf.microport.com/